AU2002366384A1 - Insulin and igf-1 receptor agonists and antagonists - Google Patents

Insulin and igf-1 receptor agonists and antagonists

Info

Publication number
AU2002366384A1
AU2002366384A1 AU2002366384A AU2002366384A AU2002366384A1 AU 2002366384 A1 AU2002366384 A1 AU 2002366384A1 AU 2002366384 A AU2002366384 A AU 2002366384A AU 2002366384 A AU2002366384 A AU 2002366384A AU 2002366384 A1 AU2002366384 A1 AU 2002366384A1
Authority
AU
Australia
Prior art keywords
igf
antagonists
insulin
receptor agonists
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002366384A
Other languages
English (en)
Other versions
AU2002366384A8 (en
Inventor
Arthur J. Blume
Jakob Brandt
Renee Brissette
Neil I. Goldstein
Soren Ostergaard
Renuka Pillutla
Lauge Schaffer
Jane Spetzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
DGI BioTechnologies LLC
Original Assignee
Novo Nordisk AS
DGI BioTechnologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, DGI BioTechnologies LLC filed Critical Novo Nordisk AS
Publication of AU2002366384A1 publication Critical patent/AU2002366384A1/en
Publication of AU2002366384A8 publication Critical patent/AU2002366384A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002366384A 2001-09-24 2002-09-24 Insulin and igf-1 receptor agonists and antagonists Abandoned AU2002366384A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/962,756 2001-09-24
US09/962,756 US6875741B2 (en) 1998-09-02 2001-09-24 Insulin and IGF-1 receptor agonists and antagonists
PCT/US2002/030312 WO2003070747A2 (en) 2001-09-24 2002-09-24 Insulin and igf-1 receptor agonists and antagonists

Publications (2)

Publication Number Publication Date
AU2002366384A1 true AU2002366384A1 (en) 2003-09-09
AU2002366384A8 AU2002366384A8 (en) 2003-09-09

Family

ID=25506313

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002366384A Abandoned AU2002366384A1 (en) 2001-09-24 2002-09-24 Insulin and igf-1 receptor agonists and antagonists
AU2002341834A Abandoned AU2002341834A1 (en) 2001-09-24 2002-09-24 Antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002341834A Abandoned AU2002341834A1 (en) 2001-09-24 2002-09-24 Antagonists

Country Status (6)

Country Link
US (1) US6875741B2 (cg-RX-API-DMAC7.html)
EP (2) EP1432433A4 (cg-RX-API-DMAC7.html)
JP (2) JP2005505579A (cg-RX-API-DMAC7.html)
AU (2) AU2002366384A1 (cg-RX-API-DMAC7.html)
CA (2) CA2459999A1 (cg-RX-API-DMAC7.html)
WO (2) WO2003027246A2 (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US6521738B2 (en) * 1999-12-29 2003-02-18 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogs
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US20070128657A1 (en) 2002-01-23 2007-06-07 El-Gewely Mohamed R Molecular libraries
US8623822B2 (en) * 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) * 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2003089582A2 (en) * 2002-04-22 2003-10-30 Greenville Hospital System Multimeric ligands with enhanced stability
MXPA04011624A (es) * 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
EP1527161B1 (fr) * 2002-07-31 2015-10-28 Yves Saint-Laurent Parfums Cellules souches issues de tissu adipeux et cellules differenciees issues de ces cellules
US20040176291A1 (en) * 2002-09-24 2004-09-09 Elly Nedivi Methods and compositions for soluble CPG15
CA2524305C (en) * 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005032476A2 (en) * 2003-09-30 2005-04-14 Massachusetts Institute Of Technology Methods and compositions for cpg15-2
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US7781393B2 (en) 2004-02-25 2010-08-24 Dana-Farber Cancer Institute, Inc. Methods for inhibiting tumor cell growth
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
US7723483B2 (en) 2004-05-07 2010-05-25 The University Of North Carolina At Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-I
EP1781324A2 (en) * 2004-08-20 2007-05-09 Novo Nordisk A/S Pharmaceutically active insulin receptor-modulating molecules
WO2006045710A2 (en) * 2004-10-27 2006-05-04 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
KR101242543B1 (ko) * 2004-10-27 2013-03-22 유니버시티 오브 덴버 부신피질 자극 호르몬 유사체 및 관련 방법
CA2589885A1 (en) * 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
ES2732623T3 (es) 2005-01-06 2019-11-25 Innate Pharma Sa Tratamientos y métodos de combinación anti-KIR
CA2602375C (en) 2005-03-23 2018-07-24 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
MX2007012896A (es) * 2005-04-15 2007-12-10 Schering Corp Metodos y composiciones para tratamiento o prevencion de cancer.
BRPI0611800A2 (pt) 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
PL2100614T3 (pl) * 2005-06-17 2014-02-28 Imclone Llc Przeciwciała przeciwko PDGFR alfa do zastosowania w leczeniu guzów nowotworowych
WO2007011610A2 (en) * 2005-07-18 2007-01-25 Acologix, Inc. Protein formulation for promoting hard tissue formation
CN101321780A (zh) * 2005-10-05 2008-12-10 诺沃-诺迪斯克有限公司 胰岛素受体拮抗剂及相关组合物、用途和方法
MX2008009977A (es) * 2006-02-03 2009-02-27 Imclone Llc Antagonistas de receptor de factor de crecimiento de tipo insulina (igf-ir) como auxiliares para el tratamiento de cancer de prostata.
US7884078B2 (en) * 2006-02-10 2011-02-08 Massachusetts Institute Of Technology CPG15 compounds as insulin receptor and insulin-like growth factor receptor agonists
EP2468767B1 (en) 2006-06-22 2015-10-28 Walter and Eliza Hall Institute of Medical Research Structure of the insulin receptor ectodomain
US20080064039A1 (en) * 2006-07-06 2008-03-13 Pienkos Philip T Dominant negative ligand drug discovery system
AU2008244496A1 (en) 2007-04-24 2008-11-06 Antyra Inc. IGF-1R binding proteins and antagonists
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EA201500156A3 (ru) 2008-01-03 2017-09-29 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
US8481485B2 (en) 2008-12-19 2013-07-09 Indiana University Research And Technology Corporation Insulin analogs
EP2376099A4 (en) * 2008-12-19 2012-04-25 Univ Indiana Res & Tech Corp INSULIN AGAIN YL-BASED GROWTH FACTORS WITH HIGH ACTIVITY AT THE INSULIN RECEPTOR
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
AU2010253863B2 (en) * 2009-05-28 2016-01-28 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
CA2771328A1 (en) * 2009-08-28 2011-03-03 Bayer Healthcare Llc Cofactors for thrombin activation of factor vii and uses thereof
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
CA2803164C (en) 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
EP2712423A4 (en) * 2011-02-25 2015-06-10 Wellstat Diagnostics Llc Assays for detecting enzymatic activity
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2717924A4 (en) * 2011-06-10 2015-04-22 Harvard College MODULATION OF BETA CELL PROLIFERATION IN THE PANCREATIC GLAND
CA2852127C (en) 2011-11-11 2020-10-27 Duke University Combination drug therapy for the treatment of solid tumors
WO2013096386A1 (en) 2011-12-20 2013-06-27 Indiana University Research And Technology Corporation Ctp-based insulin analogs for treatment of diabetes
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
BR112015004119A2 (pt) 2012-08-31 2017-08-08 Univ North Carolina Chapel Hill anticorpos monoclonais para melhorar ou inibir o fator de crescimento semelhante à insulina tipo 1 (igf-1)
JP6387008B2 (ja) 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリンアナローグダイマー
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
WO2017069627A1 (en) 2015-10-23 2017-04-27 Universiteit Twente Integrin binding peptides and uses thereof
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
US20230055519A1 (en) * 2020-01-16 2023-02-23 The Translational Genomics Research Institute Methods of identifying synthetic molecular binding agents
EP4185608A4 (en) * 2020-07-23 2024-08-21 University of Florida Research Foundation, Inc. INSULIN RECEPTOR-MEDIATED ENHANCEMENT OF GENE TRANSFER

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
EP0378671B1 (en) * 1988-06-30 1997-03-12 City Of Hope Insulinomimetic and insulin receptor binding site peptides
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH07508025A (ja) 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
DE4432943A1 (de) 1994-09-15 1996-03-21 Radulescu Razvan T Dr Med M D Numerical Mirror Image Strategy (NUMIS)
RU2078769C1 (ru) 1995-08-18 1997-05-10 Научно-исследовательский институт биомедицинской химии РАМН Пептидный фрагмент, обладающий биологической активностью инсулина
WO1997007827A1 (en) 1995-08-22 1997-03-06 Thomas Jefferson University Gab1, A Grb2 BINDING PROTEIN, AND COMPOSITIONS FOR MAKING AND METHODS OF USING THE SAME
US6028053A (en) * 1995-10-27 2000-02-22 Mount Sinai Hospital Corporation Peptide inhibitors of a phosphotyrosine-binding domain containing protein
JP2001501455A (ja) 1996-06-07 2001-02-06 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白をコードするポリヌクレオチド
CA2278023A1 (en) * 1997-01-15 1998-07-23 Telik, Inc. Modulators of insulin receptor activity
DE69834828T2 (de) 1997-11-27 2007-01-04 Commonwealth Scientific And Industrial Research Organisation Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
WO2000040613A1 (en) 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
WO2001072771A2 (en) * 2000-03-29 2001-10-04 Dgi Biotechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists

Also Published As

Publication number Publication date
AU2002341834A1 (en) 2003-04-07
EP1496935A2 (en) 2005-01-19
EP1432433A2 (en) 2004-06-30
WO2003070747A3 (en) 2004-11-11
JP2005517741A (ja) 2005-06-16
EP1432433A4 (en) 2006-08-30
CA2460055A1 (en) 2003-08-28
CA2459999A1 (en) 2003-04-03
WO2003027246A3 (en) 2003-07-31
WO2003027246A2 (en) 2003-04-03
US6875741B2 (en) 2005-04-05
US20030195147A1 (en) 2003-10-16
JP2005505579A (ja) 2005-02-24
AU2002366384A8 (en) 2003-09-09
EP1496935A4 (en) 2006-06-07
WO2003070747A2 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
AU2002366384A1 (en) Insulin and igf-1 receptor agonists and antagonists
AU2002347022A1 (en) Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
AU2003236205A1 (en) Glucagon antagonists/inverse agonists
AU2002314433A1 (en) Ephrin-tie receptor materials and methods
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
AU7645700A (en) Single-chain antagonist polypeptides
AU2002367424A1 (en) Androgen receptor antagonists
AU2002223501A1 (en) Glucagon antagonists/inverse agonists
IL165499A (en) Vpac2 receptor agonist polypeptides, pharmaceutical compositions comprising them and uses thereof
AU2002321878A1 (en) Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
AU2003255501A1 (en) Cxcr4 receptor antagonists
AUPP380498A0 (en) Egf receptor agonists and antagonists
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
AU2001225663A1 (en) A composition comprising a combination of receptor agonists and antagonists
AU2002365655A1 (en) 5-ht7 receptor antagonists
AU2001290772A1 (en) Alpha v integrin receptor antagonists
AU6232300A (en) Receptors and associated proteins
IL176223A0 (en) The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU5861900A (en) Receptor agonists and antagonists
AU2002226048A1 (en) Urotensin-ii receptor antagonists
AU2002359524A1 (en) P2x7 receptor antagonists
AU2002325164A1 (en) Receptor, the use thereof, and mouse antibodies
AU2001249573A1 (en) Chemokine receptor antagonists
AU5297299A (en) Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase